What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Asthma
- Disease
Mika J. Mäkelä mainly focuses on Immunology, Asthma, Allergy, Internal medicine and Pediatrics.
The Inflammation, Allergic sensitization and Immunoglobulin E research Mika J. Mäkelä does as part of his general Immunology study is frequently linked to other disciplines of science, such as European union, therefore creating a link between diverse domains of science.
His biological study spans a wide range of topics, including Quality of life, Intensive care medicine and Atopic dermatitis.
His study in Allergy is interdisciplinary in nature, drawing from both Family medicine and MEDLINE.
His research integrates issues of Gastroenterology, Placebo, Surgery and Food allergy in his study of Internal medicine.
In his research on the topic of Pediatrics, Odds ratio, Gram-positive bacteria and Bacteria is strongly related with Atopy.
His most cited work include:
- Environmental biodiversity, human microbiota, and allergy are interrelated (572 citations)
- Viruses and Bacteria in the Etiology of the Common Cold (568 citations)
- Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs (384 citations)
What are the main themes of his work throughout his whole career to date?
Mika J. Mäkelä mostly deals with Immunology, Asthma, Allergy, Internal medicine and Pediatrics.
His work on Immunology deals in particular with Immunoglobulin E, Sensitization, Allergen, Inflammation and Ovalbumin.
His Asthma study combines topics from a wide range of disciplines, such as Airway and Respiratory system.
When carried out as part of a general Allergy research project, his work on Food allergy is frequently linked to work in Demography, therefore connecting diverse disciplines of study.
The Internal medicine study combines topics in areas such as Gastroenterology, Placebo, Surgery and Cardiology.
His research in Antibody intersects with topics in Antigen and Virology.
He most often published in these fields:
- Immunology (39.58%)
- Asthma (34.82%)
- Allergy (25.60%)
What were the highlights of his more recent work (between 2018-2021)?
- Asthma (34.82%)
- Internal medicine (23.51%)
- Immunology (39.58%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Asthma, Internal medicine, Immunology, MEDLINE and Allergy.
His Asthma research is multidisciplinary, relying on both Pediatrics, Lung function and Respiratory system.
Mika J. Mäkelä has researched Internal medicine in several fields, including Omalizumab and Cardiology.
His Immunology study combines topics in areas such as School age child, Smooth muscle and Bronchial inflammation.
His MEDLINE research includes themes of Position paper, Environmental health, Immunization, Intensive care medicine and Wheat allergy.
He specializes in Allergy, namely Food allergy.
Between 2018 and 2021, his most popular works were:
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma (32 citations)
- Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. (30 citations)
- Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden. (28 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Asthma
His primary areas of investigation include Asthma, Internal medicine, Immunology, Cochrane Library and Cost effectiveness.
Mika J. Mäkelä combines subjects such as Tobacco smoke, Environmental health, Allergy, Global health and Lung function with his study of Asthma.
His work carried out in the field of Allergy brings together such families of science as Pharmacy, Polypharmacy, COPD and Physiology.
His Internal medicine research is multidisciplinary, incorporating perspectives in Food allergy and Cardiology.
His Immunology research is mostly focused on the topic Immunotherapy.
In his study, which falls under the umbrella issue of Cochrane Library, Adverse effect, Rate ratio, Omalizumab and Benralizumab is strongly linked to Dupilumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
